VCEL
Vericel Corporation (VCEL)
$
43About Vericel Corporation (VCEL)
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Details
Daily high
$47.55
Daily low
$45.85
Price at open
$46.26
52 Week High
$63.00
52 Week Low
$39.12
Market cap
2.4B
Dividend yield
0.00%
Volume
373,396
Avg. volume
466,122
P/E ratio
256.93
Vericel Corporation News
Details
Daily high
$47.55
Daily low
$45.85
Price at open
$46.26
52 Week High
$63.00
52 Week Low
$39.12
Market cap
2.4B
Dividend yield
0.00%
Volume
373,396
Avg. volume
466,122
P/E ratio
256.93